Your browser doesn't support javascript.
Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial.
Araimo, Fabio; Imperiale, Carmela; Tordiglione, Paolo; Ceccarelli, Giancarlo; Borrazzo, Cristian; Alessandri, Francesco; Santinelli, Letizia; Innocenti, Giuseppe Pietro; Pinacchio, Claudia; Mauro, Vera; Recchia, Gregorio Egidio; Zancla, Serena; Calò, Andrea; Poscia, Roberto; Ruberto, Franco; d'Ettorre, Gabriella; Bilotta, Federico; Mastroianni, Claudio; Pugliese, Francesco.
  • Araimo F; Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy.
  • Imperiale C; Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy.
  • Tordiglione P; Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy.
  • Ceccarelli G; Department of Anesthesia and Intensive Care Medicine, Azienda Universitaria-Ospedaliera Policlinico Umberto I, Rome, Italy.
  • Borrazzo C; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Alessandri F; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Santinelli L; Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy.
  • Innocenti GP; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Pinacchio C; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Mauro V; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Recchia GE; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Zancla S; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Calò A; Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy.
  • Poscia R; Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy.
  • Ruberto F; Department of Anesthesia and Intensive Care Medicine, Azienda Universitaria-Ospedaliera Policlinico Umberto I, Rome, Italy.
  • d'Ettorre G; Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy.
  • Bilotta F; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Mastroianni C; Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy.
  • Pugliese F; Department of Anesthesia and Intensive Care Medicine, Azienda Universitaria-Ospedaliera Policlinico Umberto I, Rome, Italy.
J Med Virol ; 93(4): 2210-2220, 2021 04.
Article in English | MEDLINE | ID: covidwho-893240
Semantic information from SemMedBD (by NLM)
1. Pneumonia PROCESS_OF Patients
Subject
Pneumonia
Predicate
PROCESS_OF
Object
Patients
2. systemic administration TREATS Disease Progression
Subject
systemic administration
Predicate
TREATS
Object
Disease Progression
3. Disease Progression PROCESS_OF Patients
Subject
Disease Progression
Predicate
PROCESS_OF
Object
Patients
4. Pneumonia PROCESS_OF Patients
Subject
Pneumonia
Predicate
PROCESS_OF
Object
Patients
5. systemic administration TREATS Disease Progression
Subject
systemic administration
Predicate
TREATS
Object
Disease Progression
6. Disease Progression PROCESS_OF Patients
Subject
Disease Progression
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
The evaluation of new therapeutic resources against coronavirus disease 2019 (COVID-19) represents a priority in clinical research considering the minimal options currently available. To evaluate the adjuvant use of systemic oxygen-ozone administration in the early control of disease progression in patients with COVID-19 pneumonia. PROBIOZOVID is an ongoing, interventional, randomized, prospective, and double-arm trial enrolling patient with COVID-19 pneumonia. From a total of 85 patients screened, 28 were recruited. Patients were randomly divided into ozone-autohemotherapy group (14) and control group (14). The procedure consisted in a daily double-treatment with systemic Oxygen-ozone administration for 7 days. All patients were treated with ad interim best available therapy. The primary outcome was delta in the number of patients requiring orotracheal-intubation despite treatment. Secondary outcome was the difference of mortality between the two groups. Moreover, hematological parameters were compared before and after treatment. No differences in the characteristics between groups were observed at baseline. As a preliminary report we have observed that one patient for each group needed intubation and was transferred to ITU. No deaths were observed at 7-14 days of follow up. Thirty-day mortality was 8.3% for ozone group and 10% for controls. Ozone therapy did not significantly influence inflammation markers, hematology profile, and lymphocyte subpopulations of patients treated. Ozone therapy had an impact on the need for the ventilatory support, although did not reach statistical significance. Finally, no adverse events related to the use of ozone-autohemotherapy were reported. Preliminary results, although not showing statistically significant benefits of ozone on COVID-19, did not report any toxicity.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Oxygen / Ozone / COVID-19 Subject: Oxygen / Ozone / COVID-19 Type of study: Controlled clinical trial / Observational study Language: English Journal: J Med Virol Clinical aspect: Etiology Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Oxygen / Ozone / COVID-19 Subject: Oxygen / Ozone / COVID-19 Type of study: Controlled clinical trial / Observational study Language: English Journal: J Med Virol Clinical aspect: Etiology Year: 2021
...